Optimal antibiotic therapy in bronchopulmonary infections.
Therapy of bronchopulmonary infections has evolved in the past 30 years. Only in the therapy of pneumococcal infections have, precise dosage programs been developed. Therapy of pneumococcal infection is optimal with penicillin G in low dosage. None of the newer agents has altered morbidity or mortality. The best agent for the treatment of pneumonia due to Staphylococcus aureus or members of the Enterobacteriaceae has not been established. Use of combination therapy consisting of an anti-Pseudomonas penicillin and an aminoglycoside has been shown to offer the greatest success in the treatment of Pseudomonas pulmonary infections. The optimal antibiotic and dosage program for the treatment of acute bacterial exacerbations of chronic bronchitis has yet to be defined. Further comparative studies of the chemotherapy of pulmonary infections are necessary.
D000617:Aminoglycosides / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001982:Bronchial Diseases / Q000188:drug therapy*; D001991:Bronchitis / Q000188:drug therapy; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy*; D010406:Penicillins / Q000627:therapeutic use; D011008:Pneumococcal Infections / Q000188:drug therapy; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy; D011023:Pneumonia, Staphylococcal / Q000188:drug therapy; D011552:Pseudomonas Infections / Q000188:drug therapy
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D010406:Penicillins